Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of.
BT Group's Mark Lidiard, veteran of several FTSE 100 IR and comms teams, to retire irmagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from irmagazine.com Daily Mail and Mail on Sunday newspapers.
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 ­ Lead program TG4050 to deliver data in 2024. ­ Advancements in other clinical pr.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation activity to.